Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate.
The specific opiate antagonists--naloxone and naltrexone--attenuated or abolished the electrical seizure activity, behavioral abnormalities, and increased striatal dopamine content produced by gamma-butyrolactone, the prodrug of gamma-hydroxybutyrate. The effects of naloxone and naltrexone were dose-dependent. These data suggest that gamma-hydroxybutyric acid exerts its effects by action either at the opiate receptor or on enkephalinergic systems, which may be involved in petit mal epilepsy.
D015107:4-Butyrolactone / Q000494:pharmacology*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002375:Catalepsy / Q000139:chemically induced; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D004569:Electroencephalography; D004837:Epinephrine / Q000378:metabolism; D005663:Furans / Q000494:pharmacology*; D006801:Humans; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D009271:Naltrexone / Q000494:pharmacology; D051381:Rats
D005663:Furans; D009270:Naloxone; D009271:Naltrexone; D015107:4-Butyrolactone; D004298:Dopamine; D004837:Epinephrine